Emcure Pharmaceuticals strengthened its global partnerships, expanded its international portfolio and increased investments in research and development during FY2025-26, as the company continued to build its presence across key pharmaceutical markets.

Strategic collaborations with global pharmaceutical companies remained a key component of Emcure’s growth strategy during the year.

The company entered into an agreement with Novo Nordisk for Poviztra (semaglutide), strengthening its presence in metabolic therapies through exclusive distribution. 

Emcure also expanded its partnership with Sanofi to include the oral anti-diabetic brands Amaryl and Cetapin, further strengthening its cardio-metabolic portfolio.

In March 2026, Emcure entered into an agreement with Roche covering select brands in nephrology and transplant care. The partnership expands the company’s presence in a therapeutic segment where it already has an established foothold.

Emcure also completed the acquisition of the remaining minority stake in Zuventus, giving it full ownership of the business and enabling complete consolidation.

International portfolio expands

Emcure launched more than 35 products across international markets during FY26, with several developments strengthening its presence in complex and specialty products.

The company entered the European market with Liposomal Amphotericin B, becoming the first generic entrant for the complex injectable molecule. Emcure said it secured scale-up and regulatory approvals for the product during the year.

The acquisition of the Manx portfolio further strengthened its European platform by expanding its product basket and market presence.

In Canada, Emcure completed the acquisition of Cutimed, a dermatology-focused business that complements its position among the top 10 generic players in the Canadian market.

The company also reported continued growth in Canada, supported by market-share gains and improved product availability. Its Rest of World business also expanded across markets in Asia, Africa and Latin America.

R&D investment rises

Emcure continued to step up investments in research and innovation, with R&D expenditure reaching Rs. 3,835 million, equivalent to 4.2% of sales and representing an increase of 50 basis points over the previous year.

The company’s innovation pipeline spans complex injectables, biosimilars and advanced drug-delivery systems.

Its bevacizumab ophthalmic biosimilar for wet age-related macular degeneration received endorsement from the CDSCO’s Subject Expert Committee. Emcure expects to launch the product in FY2026-27, subject to regulatory approval.

The company also remains one of six global voluntary licensees for Gilead’s lenacapavir for HIV treatment. Emcure has filed the Drug Master File and is targeting product registration during FY2026-27.

AI and sustainability remain focus areas

Technology and digital transformation also remained priorities during FY26, with Emcure outlining plans to integrate artificial intelligence across regulatory documentation, quality investigations and sales intelligence.

The company is also strengthening its quality systems through digital platforms and exploring AI-assisted approaches to improve regulatory and operational processes.

On the sustainability front, Emcure reported that renewable power accounted for 64.7% of its total energy mix during FY26, highlighting its continued focus on reducing its environmental footprint while expanding its global operations.